Loading...
Loading...
IMV| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 9,979.0K |
| Operating I/L | -9,979.0K |
| Other Income/Expense | 72.0K |
| Interest Income | 72.0K |
| Pretax | -9,907.0K |
| Income Tax Expense | -144.0K |
| Net Income/Loss | -9,763.0K |
IMV Inc. is a clinical-stage immuno-oncology company specializing in developing therapies for solid and hematological cancers. The company's portfolio is based on its DPX immune-educating technology platform, with lead drug candidate maveropepimut-S in Phase II clinical trials for various cancers, including diffuse large B cell lymphoma, ovarian cancer, and bladder, liver, and microsatellite instability high tumors. Additionally, IMV Inc. is developing DPX-SurMAGE for bladder cancer and DPX-COVID-19 and DPX-RSV for infectious diseases.
